Today, one in five American adults experiences a mental health issue, and one in 10 young people experiences a period of major depression. The number of people struggling with conditions such as anxiety, depression, post-traumatic stress disorder, and substance abuse…
This article first appeared in INQUIRY: The Journal of Health Care Organization, Provision, and Financing. Abstract Payers are demanding that US health care become more accountable and integrated, posing new demands for physicians and the organizations that partner with them…
On January 23rd, the National Academy of Sciences, Engineering and Medicine (NASEM) held the Affordable Drugs Stakeholder Meeting. This was the third of three meetings for the Ensuring Patient Access to Affordable Drug Therapies committee, an ad hoc committee within…
When public policy, institutional practices, and other social and economic structures combine to perpetuate inequity between people of different ethnic groups, it is known as structural racism. This phenomenon – while not an individual character flaw or personal failure –…
By Murray Ross, PhD, Vice President and Institute for Health Policy Director
Technology and communications that support health care delivery empower people to take an active role in their care. “It’s shifting who is in the driver’s seat,” says Terhilda Garrido, Vice President of Health Information Technology Transformation/Analytics at Kaiser Permanente. “Not…
A July 2015 Perspective in the Journal of Academic Medicine is co-authored by former senior director of the Institute for Health Policy, Beth Roemer, MPH, along with Theresa Azevedo, and Bruce Blumberg, MD. The piece explains how in the era…
Pharmaceutical prices in the United States are extraordinarily high and have contributed to an unsustainable level of spending on drugs. The U.S. spends more on pharmaceuticals than any other developed nation in the world: $1,010 per capita, representing 12 percent…
Health Affairs Editor-in-Chief Alan Weil recently surprised readers with his comments on “Why I Oppose Payment Reform.” Those of us who fell for that bit of click bait discovered that, of course, he does not oppose reform. Rather, he wanted…
With the Food and Drug Administration (FDA)’s approval of Harvoni, the successor to Gilead Science’s Sovaldi, the alarm bells have officially rung on breakthrough hepatitis C treatments. One can’t open a newspaper or scan a Twitter feed without stumbling on at…
